InnaVirVax, an Evry, a Paris biopark-based biopharmaceutical company specialized in research and development of therapeutic solutions for infectious and major chronic diseases, raised €3.6m ($4m) in its third funding round.
Backers included The FCPR CapDecisif 2, G1J Ile-de-France, Pradeyrol Development, Fa Dièse and FRCI (Fonds Régional de Co-Investissement d’Ile-de-France) funds.
The company intends to use the funds to advance the PROTHEVIH collaborative project and accelerate the development of VAC-3S, which is currently in Phase 2 of clinical trials.
Led by Joël Crouzet, CEO, InnaVirVax is a biopharmaceutical company specializing in research and development on therapeutic solutions for infectious diseases and major chronic diseases. VAC-3S is an immunotherapy currently in clinical phase 2. Initiated in 2014, the company’s phase 2a, European, randomized, double-blind and placebo-controlled study has recruited 86 patients living with HIV in 13 clinical centres in France, Germany and in Spain.